S Malcolm

1.1k total citations
19 papers, 604 citations indexed

About

S Malcolm is a scholar working on Psychiatry and Mental health, Neurology and Physiology. According to data from OpenAlex, S Malcolm has authored 19 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Psychiatry and Mental health, 5 papers in Neurology and 4 papers in Physiology. Recurrent topics in S Malcolm's work include Attention Deficit Hyperactivity Disorder (3 papers), Botulinum Toxin and Related Neurological Disorders (3 papers) and Schizophrenia research and treatment (3 papers). S Malcolm is often cited by papers focused on Attention Deficit Hyperactivity Disorder (3 papers), Botulinum Toxin and Related Neurological Disorders (3 papers) and Schizophrenia research and treatment (3 papers). S Malcolm collaborates with scholars based in United States, Greece and United Kingdom. S Malcolm's co-authors include Calvin R. Sumner, Douglas K. Kelsey, Kory Schuh, Virginia K. Sutton, Jill Gonzales, Daniel L. Coury, Keith E. Saylor, Humberto Quintana, Albert J. Allen and Charles D. Casat and has published in prestigious journals such as Journal of Biological Chemistry, PEDIATRICS and Biochemical Journal.

In The Last Decade

S Malcolm

19 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S Malcolm United States 10 351 146 122 107 98 19 604
Michael D. Köhnke Germany 11 122 0.3× 73 0.5× 61 0.5× 41 0.4× 69 0.7× 16 488
Sarah Farrand Australia 12 172 0.5× 207 1.4× 53 0.4× 56 0.5× 98 1.0× 31 539
R. Verde United States 6 149 0.4× 30 0.2× 98 0.8× 146 1.4× 28 0.3× 12 533
Rio Bianchini Italy 7 190 0.5× 24 0.2× 89 0.7× 101 0.9× 50 0.5× 8 380
Catherine Schmidt‐Mutter France 15 80 0.2× 104 0.7× 79 0.6× 30 0.3× 59 0.6× 34 659
Christoph Klawe Germany 13 132 0.4× 54 0.4× 68 0.6× 96 0.9× 65 0.7× 21 725
Elizabeth Hill United States 6 158 0.5× 73 0.5× 120 1.0× 25 0.2× 21 0.2× 9 346
Lovisa Berggren United States 13 178 0.5× 35 0.2× 59 0.5× 31 0.3× 17 0.2× 27 392
Fayçal Mouaffak France 15 224 0.6× 32 0.2× 66 0.5× 96 0.9× 48 0.5× 31 492
Dhamidhu Eratne Australia 11 213 0.6× 231 1.6× 47 0.4× 20 0.2× 97 1.0× 48 512

Countries citing papers authored by S Malcolm

Since Specialization
Citations

This map shows the geographic impact of S Malcolm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Malcolm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Malcolm more than expected).

Fields of papers citing papers by S Malcolm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Malcolm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Malcolm. The network helps show where S Malcolm may publish in the future.

Co-authorship network of co-authors of S Malcolm

This figure shows the co-authorship network connecting the top 25 collaborators of S Malcolm. A scholar is included among the top collaborators of S Malcolm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Malcolm. S Malcolm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Irving, Gordon, Robert J. Tanenberg, Joel Raskin, R. Risser, & S Malcolm. (2014). Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. International Journal of Clinical Practice. 68(9). 1130–1140. 25 indexed citations
3.
Vollmer, Timothy, Michael J. Robinson, Richard C. Risser, & S Malcolm. (2013). A Randomized, Double‐Blind, Placebo‐Controlled Trial of Duloxetine for the Treatment of Pain in Patients with Multiple Sclerosis. Pain Practice. 14(8). 732–744. 39 indexed citations
4.
5.
Williams, David W., et al.. (2008). Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study. Current Medical Research and Opinion. 24(2). 449–460. 14 indexed citations
6.
7.
Allen, A.J., Douglas K. Kelsey, Calvin R. Sumner, et al.. (2003). P.6.068 Once-daily atomoxetine in childhood ADHD: Continuous symptom relief. European Neuropsychopharmacology. 13. S454–S455. 6 indexed citations
8.
Kinon, Bruce J., Bruce R. Basson, J. A. Gilmore, S Malcolm, & Virginia L. Stauffer. (2000). Strategies for Switching From Conventional Antipsychotic Drugs or Risperidone to Olanzapine. The Journal of Clinical Psychiatry. 61(11). 833–840. 61 indexed citations
9.
Kinon, Bruce J., et al.. (2000). Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. European Neuropsychopharmacology. 10. 306–306. 7 indexed citations
10.
Kinon, Bruce J., Bruce R. Basson, Jeff Wang, & S Malcolm. (2000). Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Psychoneuroendocrinology. 25. S62–S62. 5 indexed citations
11.
Kinon, Bruce J., et al.. (2000). Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Schizophrenia Research. 41(1). 194–195. 7 indexed citations
12.
Cockburn, F., J. Paul Chapple, A. F. Heeley, et al.. (1993). PHENYLKETONURIA DUE TO PHENYLALANINE-HYDROXYLASE DEFICIENCY - AN UNFOLDING STORY. UCL Discovery (University College London). 2 indexed citations
13.
Malcolm, S, et al.. (1993). The molecular detection of the pseudodeficiency allele for arylsulphatase A in patients with neurological symptoms and low arylsulphatase A activity. Journal of Inherited Metabolic Disease. 16(6). 1048–1049. 2 indexed citations
14.
Katz, F, et al.. (1990). The use of locus-specific minisatellite probes to check engraftment following allogeneic bone marrow transplantation for severe combined immunodeficiency disease.. PubMed. 5(3). 199–204. 7 indexed citations
15.
Malcolm, S, et al.. (1986). Purification and comparison of the structures of human liver acidic α-d-mannosidases A and B. Biochemical Journal. 233(1). 65–72. 31 indexed citations
16.
Guilfoyle, Tom J., Gretchen Hagen, & S Malcolm. (1984). Immunological studies on plant DNA-dependent RNA polymerases with antibodies raised against individual subunits.. Journal of Biological Chemistry. 259(1). 640–648. 20 indexed citations
17.
Guilfoyle, Tom J., Gretchen Hagen, & S Malcolm. (1984). Size heterogeneity of the largest subunit of nuclear RNA polymerase II. An immunological analysis.. Journal of Biological Chemistry. 259(1). 649–653. 25 indexed citations
18.
Malcolm, S, et al.. (1983). Eukaryotic DNA-dependent RNA polymerases: structural and immunological characterization.. PubMed. 7. 241–61. 1 indexed citations
19.
Guilfoyle, Tom J. & S Malcolm. (1980). The amounts, subunit structures, and template-engaged activities of RNA polymerases in germinating soybean axes. Developmental Biology. 78(1). 113–125. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael D. Köhnke Breakdown of academic impact, for papers by Sarah Farrand Breakdown of academic impact, for papers by R. Verde Breakdown of academic impact, for papers by Rio Bianchini Breakdown of academic impact, for papers by Catherine Schmidt‐Mutter Breakdown of academic impact, for papers by Christoph Klawe Breakdown of academic impact, for papers by Elizabeth Hill Breakdown of academic impact, for papers by Lovisa Berggren Breakdown of academic impact, for papers by Fayçal Mouaffak Breakdown of academic impact, for papers by Dhamidhu Eratne
Rankless by CCL
2026